BioXcel Therapeutics, Inc. 10-Q filing
Filed 2026-05-15 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001104659-26-061769
- Form type
- 10-Q
- CIK
- 0001720893
- Primary document
- https://www.sec.gov/Archives/edgar/data/1720893/000110465926061769/btai-20260331x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BioXcel Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $206,000 | - | - |
| Cost Of Revenue | $283,000 | - | - |
| Operating Income | $-10.2M | - | - |
| Net Income | $-12.7M | - | - |
| Eps Basic | -0.54 | - | - |
| Eps Diluted | -0.54 | - | - |
| Cash And Equivalents | $17.2M | - | - |
| Total Assets | $34.0M | - | - |
| Total Liabilities | $139.6M | - | - |
| Shareholders Equity | $-105.5M | - | - |
| Operating Cash Flow | $-11.8M | - | - |
| Capital Expenditures | $0 | - | - |